Discover
ALLR
Allarity Therapeutics, Inc.
1.33
2 x 0.96
2 x 1.67
bid
ask
+
0.04
3.10%
2 @ 04:17 AM
1.36 +0.03 (2.26%)
| Ytd | 23.15% | |
| 1y | 27.88% |
1.28
day range
1.34
0.77
52 week range
2.35
| Open | 1.28 | Prev Close | 1.29 | Low | 1.28 | High | 1.34 | Mkt Cap | 21.16M |
| Vol | 121.81K | Avg Vol | 195.26K | EPS | -0.70 | P/E | N/A | Forward P/E | -0.02 |
| Beta | 0.29 | Short Ratio | 0.30 | Inst. Own | 2.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.47 | 200-d Avg | 1.28 | 1yr Est | 5.00 |
ALLR News
benzinga.com
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predict
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2
globenewswire.com
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until A
seekingalpha.com
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
benzinga.com
Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congr
The poster outlines the scientific background, study design, and clinical rationale for the Company&
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy an